FDA conditionally approves Liavium-CA1 for canine CM/SM pain: full analysis

The FDA has conditionally approved Liavium-CA1, a pregabalin chewable tablet, for dogs with Chiari-like malformation and syringomyelia, marking a notable regulatory step for a condition that can be difficult to diagnose, painful to manage, and frustrating for both clinicians and pet parents. The May 12, 2026 approval gives U.S. veterinarians a product specifically labeled for managing pain and clinical signs associated with CM/SM, rather than relying entirely on compounded or extra-label approaches. (fda.gov)

That matters because CM/SM has been a recognized problem in predisposed toy and small breeds for years, particularly Cavalier King Charles Spaniels, but the clinical picture is often messy. Reviews in the veterinary literature describe a syndrome tied to skull and craniocervical malformation, altered cerebrospinal fluid flow, and neuropathic pain, with signs that can include cervical pain, phantom scratching, exercise intolerance, gait changes, and other variable neurologic complaints. MRI has become central to diagnosis, but the literature also notes that imaging findings and clinical signs do not always line up neatly, which helps explain why treatment studies are hard to run and why FDA cited diagnostic complexity as part of the basis for conditional approval. (frontiersin.org)

According to FDA’s announcement and FOI summary, Liavium-CA1 is available in 30 mg, 90 mg, and 180 mg chewable tablets, is dosed at 5 to 10 mg/kg orally twice daily with food, and may be administered concurrently with an NSAID. Dogs under 3 kg can’t be accurately dosed. FDA said there is no approved animal drug currently marketed in the U.S. for this use, making the product an answer to an unmet animal health need under the agency’s expanded conditional approval pathway. Under that pathway, the sponsor must show safety and a reasonable expectation of effectiveness now, then continue collecting the evidence needed for full approval. (animaldrugsatfda.fda.gov)

The effectiveness case leaned heavily on published literature rather than a large pivotal field study. In the FOI summary, FDA says one 2019 randomized, placebo-controlled, double-masked crossover study in nine client-owned Cavalier King Charles Spaniels supported a reasonable expectation of effectiveness at a minimum dose of 5 mg/kg twice daily given with an NSAID. Owner pain scores and quantitative sensory testing improved during pregabalin treatment, and sedation was reported in two dogs. A second published trial helped support the upper end of the labeled dose range, but adverse effects at higher doses included reduced activity, ataxia, somnolence, increased appetite, and increased water intake, leading FDA to cap the labeled range at 10 mg/kg twice daily based in part on veterinary neurology expert input. (animaldrugsatfda.fda.gov)

Industry reaction in the available reporting has so far been limited, with dvm360 largely echoing the FDA announcement rather than surfacing outside commentary. Still, the FDA documents themselves show where expert influence entered the process: the agency says veterinary neurology experts informed dose selection to balance efficacy and tolerability. Inference: that suggests regulators were trying to align the label with how specialists already think about neuropathic pain management in CM/SM, while moving the field toward a standardized, on-label option. (dvm360.com)

Why it matters: For general practitioners and neurologists, the approval could reduce some of the ambiguity around discussing treatment options with pet parents, especially when managing chronic neuropathic pain in breeds already associated with CM/SM risk. It may also help with medical record clarity, prescribing confidence, and client communication around expected benefits and adverse effects. At the same time, this is still conditional approval, not full approval, so clinicians will need to explain that distinction clearly: FDA has determined the drug is safe and has a reasonable expectation of effectiveness, but the sponsor still has to complete the more demanding effectiveness package required for full approval. Because pregabalin is a Schedule V controlled substance and the label includes human handling precautions, practices will also need to think through storage, dispensing workflows, and counseling if a treated dog vomits or if pregnant or breastfeeding household members may be exposed. (fda.gov)

There’s also a broader signal here for veterinary drug development. FDA’s expanded conditional approval pathway was created to bring needed therapies to market sooner when full effectiveness studies are unusually difficult. The agency has used that route in other canine and feline indications in recent years, and Liavium-CA1 adds another example where a niche but serious clinical problem can support a labeled therapy before the full evidence package is complete. For companies working in specialty neurology, pain, or orphan-like companion animal indications, this approval may be read as encouragement that literature-backed, expert-informed development strategies can still reach market when conventional trials are hard to execute. (fda.gov)

What to watch: The next milestones are annual renewals of the conditional approval, real-world adoption in referral and primary care settings, and whatever confirmatory effectiveness work TriviumVet brings forward before the five-year window closes. If uptake is strong, Liavium-CA1 could become a reference point for how FDA and sponsors handle future therapies for complex, imaging-dependent neurologic diseases in dogs. (fda.gov)